Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMILIA: Trastuzumab emtansine in HER2+ advanced breast cancer
NCT00829166Phase 3Completed
- Sponsor
- Roche
- Start
- Feb 2009
- Primary completion
- Jul 2012
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 27
01
Overview
A Phase 3 trial of trastuzumab emtansine in breast cancer, sponsored by Roche. Started Feb 2009; status: completed.
02
Drugs
trastuzumab emtansine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00829166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00829166.